Teresa S. Flippo-Morton

TL;DR: The application of SLN surgery for staging the axilla following chemotherapy for women who initially had node-positive cN1 breast cancer is unclear because of high false-negative results reported in previous studies as mentioned in this paper.

TL;DR: Patients with triple-negative and HER2-positive breast cancers have the highest rates of breast-conserving surgery and pCR after neoadjuvant chemotherapy, and patients with these subtypes are most likely to be candidates for less invasive surgical approaches after chemotherapy.

TL;DR: The sentinel lymph node identification rate after NAC was higher when mapping was performed using radiolabeled colloid alone or with blue dye compared withblue dye alone, and the SLN identification rate was higher than usual when mapped with dual mapping agents.

TL;DR: SLN surgery after NAC in node positive breast cancer patients correctly identified nodal status in 84% of all patients and was associated with a false negative rate (FNR) of 12.8%.

TL;DR: The literature suggests and the data support that acceptance of RRM in the BRCA‐positive population has gradually increased over time, and consistently high rates of RRSO uptake and short intervals from time‐of‐testing to R RSO demonstrate that RRSo is still more acceptable to this population than RRM.